Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275).
AR splice variants
Biomarker
CTCs
Metastatic castration-resistant prostate cancer
PSMA
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
27
03
2022
accepted:
17
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
15
6
2022
Statut:
epublish
Résumé
Circulating tumor cells detection and ARV7 expression are associated with worse clinical outcomes in metastatic Castration-Resistant Prostate Cancer (mCRPC) undergoing Androgen Receptor Targeted Agents. ARFL, PSMA and PSA may help to refine prognostic models. In our institution, a prospective observational trial testing CTC detection in mCPRC undergoing I line ARTA therapy terminated the planned enrollment in 2020. Here, we present a pre-planned interim analysis with 18 months of median follow-up. RT-qPCR was used to determine the CTC expression of PSA, PSMA, AR and ARV7 before starting ARTA. PSA-drop, Progression-Free and Overall Survival (PFS and OS) and their correlation with CTC detection were reported. Forty-four patients were included. CTC were detected in 43.2% of patients, of whom 8.94% expressed PSA, 15.78% showed ARV7, 63.15% and 73.68% displayed ARFL and PSMA, respectively. Biochemical response was significantly improved in CTC + vs CTC- patients, with median PSA-drop of 18.5 vs 2.5 ng/ml (p = 0.03). After a median follow-up of 18 months, 50% of patients progressed. PFS was significantly longer in CTC- patients (NR vs 16 months). Eight (18.2%) patients died, a non-significant trend in terms of OS was detected in favor of CTC- patients (NR vs 29 months, p = 0.05). AR, PSA and PSMA expression in CTC + had no significant impact on PSA-drop, PFS or OS. PRIMERA-trial confirmed the CTC detection predictive importance in mCRPC patients.
Identifiants
pubmed: 35687207
doi: 10.1007/s12032-022-01756-2
pii: 10.1007/s12032-022-01756-2
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Receptors, Androgen
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
119Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Henríquez I, Roach M 3rd, Morgan TM, et al. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines. 2021;9(9):1247. https://doi.org/10.3390/biomedicines9091247 .
doi: 10.3390/biomedicines9091247
pubmed: 34572433
pmcid: 8468423
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64. https://doi.org/10.1200/JCO.1996.14.6.1756 .
doi: 10.1200/JCO.1996.14.6.1756
pubmed: 8656243
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. https://doi.org/10.1016/S0140-6736(10)61389-X .
doi: 10.1016/S0140-6736(10)61389-X
pubmed: 20888992
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. https://doi.org/10.1016/S1470-2045(14)71205-7 .
doi: 10.1016/S1470-2045(14)71205-7
pubmed: 25601341
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. https://doi.org/10.1056/NEJMoa1405095 .
doi: 10.1056/NEJMoa1405095
pubmed: 24881730
pmcid: 4418931
Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406. https://doi.org/10.1016/S1470-2045(14)70474-7 .
doi: 10.1016/S1470-2045(14)70474-7
pubmed: 25439694
Hofman MS, Emmett L, Sandhu S, et al. [
doi: 10.1016/S0140-6736(21)00237-3
pubmed: 33581798
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–102. https://doi.org/10.1056/NEJMoa1911440 .
doi: 10.1056/NEJMoa1911440
pubmed: 32343890
Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398(10295):131–42. https://doi.org/10.1016/S0140-6736(21)00580-8 .
doi: 10.1016/S0140-6736(21)00580-8
pubmed: 34246347
Cornford P, Bellmunt J, Bolla M, et al. Guidelines on prostate cancer. part ii: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42. https://doi.org/10.1016/j.eururo.2016.08.002 .
doi: 10.1016/j.eururo.2016.08.002
pubmed: 27591931
Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56. https://doi.org/10.1200/JCO.2016.70.1961 .
doi: 10.1200/JCO.2016.70.1961
pubmed: 28384066
pmcid: 5493048
Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the prophecy study. J Clin Oncol. 2019;37(13):1120–9. https://doi.org/10.1200/JCO.18.01731 .
doi: 10.1200/JCO.18.01731
pubmed: 30865549
pmcid: 6494355
Del Re M, Crucitta S, Sbrana A, et al. AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer. BJU Int. 2019. https://doi.org/10.1111/bju.14792 .
doi: 10.1111/bju.14792
pubmed: 31055861
Gorges TM, Riethdorf S, von Ahsen O, et al. Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget. 2016;7(23):34930–41. https://doi.org/10.18632/oncotarget.9004 .
doi: 10.18632/oncotarget.9004
pubmed: 27145459
pmcid: 5085200
Francolini G, Loi M, Salvestrini V, Mangoni M, Detti B, Di Cataldo V, Aquilano M, Pinzani P, Salvianti F, Desideri I, Mariotti M, Garlatti P, Stocchi G, Ciccone LP, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). Clin Exp Metastasis. 2021;38(5):451–8.
doi: 10.1007/s10585-021-10118-7
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. https://doi.org/10.1056/NEJMoa1503747 .
doi: 10.1056/NEJMoa1503747
pubmed: 26244877
pmcid: 4562797
Cattrini C, Rubagotti A, Zinoli L, et al. Role of circulating tumor cells (CTC), androgen receptor full length (AR-FL) and androgen receptor splice variant 7 (AR-V7) in a prospective cohort of castration-resistant metastatic prostate cancer patients. Cancers (Basel). 2019;11(9):1365. https://doi.org/10.3390/cancers11091365 .
doi: 10.3390/cancers11091365
Chung JS, Wang Y, Henderson J, et al. Circulating tumor cell-based molecular classifier for predicting resistance to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer. Neoplasia. 2019;21(8):802–9. https://doi.org/10.1016/j.neo.2019.06.002 .
doi: 10.1016/j.neo.2019.06.002
pubmed: 31276932
pmcid: 6612010
Francolini G, Garlatti P, Loi M, Detti B, Aquilano M, Allegra A, Guerrieri B, Salvestrini V, Pinzani P, Bellini C, Salvianti F, Stocchi G, Ciccone L, Salvatore G, Sottili M, Di Cataldo V, Desideri I, Mangoni M, Meattini I, Livi L. ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis. J Clin Oncol. 2021;39(6_suppl):118–118. https://doi.org/10.1200/JCO.2021.39.6_suppl.118 .
doi: 10.1200/JCO.2021.39.6_suppl.118
Cho H, Chung JI, Kim J, et al. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. Cancer Sci. 2021;112(2):859–70. https://doi.org/10.1111/cas.14745 .
doi: 10.1111/cas.14745
pubmed: 33232539
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O’Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND, Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–60.
doi: 10.1016/S0140-6736(21)02437-5
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.
doi: 10.1016/S1470-2045(19)30082-8
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31.
doi: 10.1056/NEJMoa1903835
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.
doi: 10.1200/JCO.19.00799
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–42.
doi: 10.1056/NEJMoa2119115
Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana Pereira, Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–303.
doi: 10.1200/JCO.20.03488
Chi Kim N, Rathkopf Dana E, Smith Matthew Raymond, Efstathiou Eleni, Attard Gerhardt, Olmos David, Lee Ji Youl, Small Eric Jay, Gomes Andrea Juliana, Roubaud Guilhem, Saad Marniza, Zurawski Bogdan, Sakalo Valerii, Mason Gary, del Corral Adam, Wang George C, Daphne Wu, Diorio Brooke, Gitlitz Angela Mennicke Lopez-, Sandhu Shahneen Kaur. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol. 2022;40(6):12–12.
doi: 10.1200/JCO.2022.40.6_suppl.012
Saad Fred, Armstrong Andrew J, Thiery-Vuillemin Antoine, Oya Mototsugu, Loredo Eugenia, Procopio Giuseppe, Janoski Juliana, de Menezes Gustavo, Girotto Colagiovanni, Arslan Cagatay, Mehra Niven, Parnis Francis, Brown Emma, Schlürmann Friederike, Joung Jae Young, Sugimoto Mikio, Poehlein Christian Heinrich, Harrington Elizabeth, Desai Chintu, Kang Jinyu, Clarke Noel. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):11–11.
doi: 10.1200/JCO.2022.40.6_suppl.011
Merseburger AS, Attard G, Boysen G, Gourgioti G, Martins K, Chowdhury S. A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE. J Clin Oncol. 2022;40(6_suppl):15–15.
doi: 10.1200/JCO.2022.40.6_suppl.015